Achilles Therapeutics announced that it has appointed Dr. Edwin Moses as Chairman of its Board of Directors. In addition, Dr. Iraj Ali, currently Interim CEO, will become the permanent, full-time CEO of the Company. Dr. Moses was most recently CEO of Ablynx NV which was acquired by Sanofi for $4.8 billion in 2018.

Edwin was CEO at Ablynx for more than 12 years and built it from a small R&D-focused organisation into a five hundred person commercial-ready business with a broad biologics pipeline including a wholly-owned product for a rare hematologic indication which was approved for use in Europe earlier this year. At Ablynx, Edwin led the Euronext Brussels listing, multiple successful private and public financings and the NASDAQ listing in 2017. He was also responsible for delivering a series of multi-billion-pound collaborations with major pharmaceutical companies.

Dr. Ali joined Achilles in January 2018 as Interim CEO, whilst also serving as a Partner of Syncona Ltd, Achilles' founding investor. He joined Syncona in 2012 and was an investment partner and Board member of Nightstar Therapeutics, Blue Earth Diagnostics and Achilles Therapeutics. Dr. Ali was previously with McKinsey & Company where he was involved in several major pharmaceutical launches across developed and emerging markets and was a co-founder of McKinsey's US launch practice and leader of speciality launches in Europe.